Future research should focus on exploring the complex regulatory networks of SETD2 and EZH2 in prostate cancer, refining current inhibitor-based treatment regimens, and enhancing combination treatment strategies to improve therapeutic outcomes and patient quality of life. This evidence concerns the gene SETD2 and prostate cancer.